Recently, the results of the 2025 "Shanghai Stock Eagle · Gold Quality" selection, guided by the China Association of Public Companies and hosted by Shanghai Securities News · www.cnstock.com, were officially announced. Biokin Pharmaceutical was honored with the "Science and Technology Innovation Award" for its groundbreaking innovations in the field of biomedicine, while the company's Chairman and Chief Scientist, Zhu Yi, received the title of "Outstanding Entrepreneur" for his exceptional industry leadership and strategic vision.

As one of Shanghai Securities News' "Gold Series" selections and high-end brand forums, "Shanghai Stock Eagle · Gold Quality" adheres to assessing the "gold content" of listed companies based on quality standards, continuously guiding high-quality development in the sector. The 2025 selection focuses on market entities actively contributing to high-quality development, recognizing outstanding listed companies and their management teams to stimulate market vitality and support the steady and long-term growth of China's capital market, serving as a "ballast stone" for deepening reforms. The "Gold Quality · Science and Technology Innovation Award" specifically highlights the core technological competitiveness of enterprises.

Biokin Pharmaceutical's dual honors at both the corporate and individual levels not only reflect the capital market's recognition of the company's scientific and technological innovation capabilities and corporate governance standards but also underscore the rising momentum of China's innovative pharmaceutical enterprises in the global biomedical field. Moving forward, Biokin Pharmaceutical will continue to prioritize innovation as its core driving force, accelerating the clinical transformation and commercialization of globally pioneering drugs. By providing patients worldwide with superior treatment options, the company aims to persistently lead the high-quality development of China's biomedical industry.